GSK (GSK) Expected to Announce Quarterly Earnings on Wednesday

GSK (NYSE:GSK - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $1.06 per share and revenue of $7.52 billion for the quarter. GSK has set its FY 2025 guidance at 2.090-2.130 EPS.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Stock Performance

Shares of NYSE GSK traded down $0.08 during mid-day trading on Friday, hitting $37.42. The stock had a trading volume of 3,909,251 shares, compared to its average volume of 4,704,552. The company has a 50 day moving average of $37.50 and a two-hundred day moving average of $36.05. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a market cap of $77.21 billion, a PE ratio of 23.53, a PEG ratio of 1.12 and a beta of 0.56. GSK has a twelve month low of $31.72 and a twelve month high of $45.93.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Shareholders of record on Friday, February 21st were paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 4.20%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, February 21st. GSK's payout ratio is presently 100.63%.

Analyst Ratings Changes

GSK has been the topic of a number of recent analyst reports. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Finally, Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Eight analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.58.

Institutional Investors Weigh In On GSK

A hedge fund recently bought a new stake in GSK stock. Brighton Jones LLC bought a new stake in GSK plc (NYSE:GSK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 15,604 shares of the pharmaceutical company's stock, valued at approximately $528,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.